Cerevel Therapeutics Holdings, Inc.
CERE · NASDAQ
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$131,912 | -$132,660 | $7,822 | -$9,765 |
| Dep. & Amort. | $1,541 | $1,504 | $1,449 | $1,353 |
| Deferred Tax | $0 | -$27,951 | -$108,499 | -$94,067 |
| Stock-Based Comp. | $20,932 | $25,222 | $17,088 | $14,508 |
| Change in WC | -$5,179 | $8,521 | $17,331 | $879 |
| Other Non-Cash | -$5,051 | $27,944 | -$7,822 | $9,765 |
| Operating Cash Flow | -$119,669 | -$97,420 | -$72,631 | -$77,327 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$271 | -$902 | -$513 | -$2,057 |
| Net Acquisitions | $0 | $149 | -$52 | -$64 |
| Inv. Purchases | -$122,649 | -$317,056 | -$213,093 | -$147,490 |
| Inv. Sales/Matur. | $142,085 | $167,750 | $265,000 | $211,300 |
| Other Inv. Act. | $0 | -$149 | $52 | $64 |
| Investing Cash Flow | $19,165 | -$150,208 | $51,394 | $61,753 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | -$75 | $508,372 | $1,195 | $6,364 |
| Stock Repurch. | -$75 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $4,475 | $508,372 | $1,195 | $37,614 |
| Financing Cash Flow | $4,475 | $508,372 | $1,195 | $37,614 |
| Forex Effect | $0 | $53,339 | $27,864 | -$31,805 |
| Net Chg. in Cash | -$96,029 | $314,083 | -$20,042 | $22,040 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $418,425 | $676,882 | $177,723 | $155,683 |
| End Cash | $322,396 | $990,965 | $157,681 | $177,723 |
| Free Cash Flow | -$119,940 | -$98,322 | -$73,144 | -$79,384 |